07:00 , Apr 1, 2013 |  BC Week In Review  |  Clinical News

Viscogel: Phase I/II data

A single-blind, Swedish Phase I/II trial in about 130 healthy volunteers showed that single ascending-doses of ViscoGel as an adjuvant to the ActHIB Hib vaccine were well tolerated and met the primary safety endpoint. Additionally,...
07:00 , Apr 30, 2012 |  BC Week In Review  |  Clinical News

Viscogel: Phase I/II started

Viscogel began a single-blind Phase I/II trial of ViscoGel in about 130 healthy volunteers. The Phase I portion will evaluate single ascending-doses of ViscoGel as an adjuvant in about 30 volunteers. The Phase II portion...
07:00 , May 2, 2011 |  BC Week In Review  |  Clinical News

V419: Phase III started

Merck and sanofi-aventis' Sanofi Pasteur S.A. vaccines unit began an open-label, international Phase III trial in about 1,440 infants to evaluate 0.5 mL intramuscular V419. Subjects will receive V419 at 2, 4, 6 and 15...
07:00 , Apr 4, 2011 |  BC Week In Review  |  Clinical News

Prevnar regulatory update

Japan's Ministry of Health, Labor and Welfare (MHLW) recommended resuming use of pediatric vaccines ActHIB from sanofi-aventis Group (Euronext:SAN; NYSE:SNY, Paris, France) and Prevenar from Pfizer after concluding that there is no causal relationship between...
07:00 , Apr 4, 2011 |  BC Week In Review  |  Clinical News

ActHIB regulatory update

Japan's Ministry of Health, Labor and Welfare (MHLW) recommended resuming use of pediatric vaccines ActHIB from sanofi-aventis and Prevenar from Pfizer Inc. (NYSE:PFE, New York, N.Y.) after concluding that there is no causal relationship between...
07:00 , Mar 21, 2011 |  BC Week In Review  |  Company News

Daiichi Sankyo, sanofi-aventis sales and marketing update

sanofi-aventis' Sanofi Pasteur S.A. vaccines unit will voluntarily recall 13 lots of its ActHIB Haemophilus influenza type b (Hib) pediatric vaccine after two syringes of the vaccine's diluent were potentially faulty. sanofi said the two...
07:00 , Mar 14, 2011 |  BC Week In Review  |  Clinical News

ActHIB regulatory update

Japan's Ministry of Health, Labor and Welfare (MHLW) suspended use of pediatric vaccines ActHIB from sanofi-aventis and Prevenar from Pfizer Inc. (NYSE:PFE, New York, N.Y.) after reports surfaced of 5 deaths in patients receiving the...
07:00 , Mar 14, 2011 |  BC Week In Review  |  Clinical News

Prevnar regulatory update

Japan's Ministry of Health, Labor and Welfare (MHLW) suspended use of pediatric vaccines ActHIB from sanofi-aventis Group (Euronext:SAN; NYSE:SNY, Paris, France) and Prevenar from Pfizer after reports surfaced of 5 deaths in patients receiving the...
07:00 , Jul 6, 2009 |  BC Week In Review  |  Clinical News

ActHIB regulatory update

sanofi-aventis' sanofi pasteur S.A. vaccines unit said that the U.S. CDC reinstated its recommendation that children receive a booster dose of Haemophilus influenza type b (Hib) vaccine after 12 months of age after the company...
07:00 , Jul 6, 2009 |  BC Week In Review  |  Clinical News

Pentacel regulatory update

sanofi-aventis' sanofi pasteur S.A. vaccines unit said that the U.S. CDC reinstated its recommendation that children receive a booster dose of Haemophilus influenza type b (Hib) vaccine after 12 months of age after the company...